Brief: Kamada Announces Availability Of Its Plasma-Derived Hyperimmune IgG Therapy For COVID-19 For Compassionate Use Treatment In Israel

Kamada

17/06/2020 12:41

June 17 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA LTD - ANNOUNCES AVAILABILITY OF ITS PLASMA-DERIVED
HYPERIMMUNE IGG THERAPY FOR COVID-19 FOR COMPASSIONATE USE
TREATMENT IN ISRAEL
    * KAMADA LTD - INTENDS TO INITIATE A PHASE 1/2 CLINICAL
STUDY IN
HOSPITALIZED COVID-19 PATIENTS IN ISRAEL DURING Q3
    * KAMADA LTD - CO, KEDRION EXPANDING CLINICAL DEVELOPMENT
PROGRAM
TO U.S. AND EXPECT TO HOLD A PRE-IND MEETING WITH FDA EARLY IN
Q3
    * KAMADA LTD - INTENDS TO MANUFACTURE FUTURE BATCHES USING
U.S.
COVID-19 CONVALESCENT PLASMA COLLECTED BY KEDRION

Source text for Eikon:  ID:nGNXBdxpw 
Further company coverage:  KMDA.TA 

 (((Reuters.Briefs@thomsonreuters.com);))